一个与膜相关的MHC-I抑制轴用于癌症免疫规避
Xufeng Chen1, Qiao Lu1, Hua Zhou2
1Department of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA; The Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
研究人员发现了一种新的癌症免疫规避机制,涉及表面蛋白质SUSD6,TMEM127和WWP2,它抑制了主要组织相容性复合体I类的呈现. 针对这一轴可以改善癌症免疫治疗反应.
科学领域:
- 免疫学
- 癌症学
- 分子生物学
背景情况:
- 免疫检查点阻塞改变了癌症治疗,但在急性髓性白血病 (AML) 等癌症中面临阻力.
- 通过主要组织相容性复合物I类 (MHC- I) 抗原呈现的免疫逃避是关键的抵抗机制.
- 识别MHC- I抗原呈现的调节者对于克服治疗耐药性至关重要.
研究的目的:
- 确定MHC-I抗原呈现的新型调节者,这些调节者有助于AML的癌症免疫逃避.
- 阐明这些调节剂抑制MHC-I功能的分子机制.
- 评估向这些调节剂在癌症治疗中的治疗潜力.
主要方法:
- 使用MHC-I引导的CRISPR-Cas9查,以识别AML中MHC-I抗原呈现的负调节者.
- 研究了包括SUSD6,TMEM127和WWP2在内的顶级调节剂在MHC-I调节和癌细胞生长中的作用.
- 描述了由SUSD6,TMEM127和MHC-I形成的分子复合体及其对MHC-I无处不在和降解的影响.
主要成果:
- 确定了SUSD6,TMEM127和WWP2作为AML中MHC-I抗原呈现的主要负调节剂.
- 证明SUSD6在AML和固体瘤中高度表达,通过CD8+T细胞依赖机制抑制MHC- I呈现和瘤生长.
- 阐明了SUSD6与TMEM127和MHC-I形成复合体,招募WWP2以调解MHC-I无处不在和溶酶体降解.
结论:
- 发现一种新的膜相关抑制轴 (SUSD6/TMEM127/WWP2),抑制MHC-I抗原呈现并促进免疫逃避.
- SUSD6/TMEM127/WWP2基因特征与癌症存活率差相关,突出其临床相关性.
- 这一抑制轴是增强白血病和固体癌症免疫疗法的有希望的治疗点.
更多相关视频
07:44Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
07:18Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
Published on: June 13, 2019
相关概念视频
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...
The Intrinsic Apoptotic Pathway
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Antigen Processing Pathways
MHC Class I: Presenting Endogenous...
